HUYA Bioscience International   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Diego CA United States (2004)

Organization Overview

First Clinical Trial
2014
NCT02697552
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

HUYABIO International, LLC. | HUYA Bioscience International | HUYA Bioscience International, LLC | HUYA BioSciences

Active Ingredients

Drugs in Phase 3 Trials (2)

chidamide (7 trials)

nivolumab (opdivo) (2 trials)

Drugs in Phase 2 Trials (2)

hbi-3000 (3 trials)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (5)

hbi-2376 (1 trial)

hbi-2438 (1 trial)

paclitaxel (taxol) (1 trial)

paroxetine (paxil) (1 trial)

trastuzumab (herceptin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 2)

Breast Neoplasms (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Leukemia-Lymphoma, Adult T-Cell (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Melanoma (Phase 3)

Neoplasm Metastasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 9